The global sales of virology is estimated to be worth USD 2,333.2 million in 2025 and anticipated to reach a value of USD 3,808.9 million by 2035. Sales are projected to rise at a CAGR of 5.0% over the forecast period between 2025 and 2035. The revenue generated by virology in 2024 was USD 2,249.5 million. The industry is anticipated to exhibit a Y-o-Y growth of 3.3% in 2024.
Virology is the study of viruses, which has major applications in the development of vaccines, and diagnosis of viral infections. Growing number of disease outbreak, increase in advancement in microbiology, along with growing adoption of genetic sequencing techniques for diagnosis of several viral diseases majorly contribute to the growth of the market.
Therefore, with an aim of remaining competitive in the market many of the pharmaceutical companies are making investments towards development of new drugs which in turn contribute significantly to the growth of the market.
Global Virology Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2024 | USD 2,249.5 million |
| Estimated Size, 2025 | USD 2,333.2 million |
| Projected Size, 2035 | USD 3,808.9 million |
| Value-based CAGR (2025 to 2035) | 5.0% |
In virology, diagnostics refer to the discovery and characterization of viruses in clinical samples, which is often aided by methods like rapid antigen tests, PCR, or ELISA. These diagnostic technologies help decide on treatment options, monitor viral loads, and detect early viral infections.
Increased awareness of viral illnesses, new developments in molecular biology, and emergence of pandemics (like COVID-19) are some factors driving the ever-expanding usage of virology diagnostic tests. Further fueling market expansion are the calls for faster and more accurate findings, better health care infrastructure, and personalized medicine.
The growing prevalence of viral illnesses, like HIV, hepatitis, and influenza, along with the growing requirement for better antiviral drugs, have significantly upsurge the use of chemotherapy with antiviral medications, which in turn anticipates the growth of the market.
Interferons have an essential role in virology. They regulate immune responses and control viral replication. In hepatitis C and multiple sclerosis, interferons are therapeutically applied to strengthen the host's antiviral immunity. The increasing use of virology, in terms of diagnosis and antiviral therapy, fuels the market as it increases the management of diseases, reduces transmission rates, and enables the production of targeted therapies, which fuels healthcare innovation and economic investment.
Comparative analysis of fluctuations in compound annual growth rate (CAGR) for the global virology market between 2024 and 2025 on six months basis is shown below. By this examination, major variations in the performance of these markets are brought to light, and also trends of revenue generation are captured hence offering stakeholders useful ideas on how to carry on with the market's growth path in any other given year. January through June covers the first part of the year called half1 (H1), while half2 (H2) represents July to December
The table presents the expected CAGR for the global virology market over several semi-annual periods spanning from 2025 to 2035. In the first half (H1) of the decade from 2024 to 2034, the business is predicted to surge at a CAGR of 5.7%, followed by a slightly slower growth rate of 5.4% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 5.7% (2024 to 2034) |
| H2 | 5.4% (2024 to 2034) |
| H1 | 5.0% (2025 to 2035) |
| H2 | 4.5% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 5.0% in the first half and decrease moderately at 4.5% in the second half. In the first half (H1) the market witnessed a decrease of 70 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
Strategic Collaboration among Pharmaceutical Companies and Research Institutes Anticipates the Growth of the Market
Strategic collaborations among pharmaceutical companies and research institutes are crucial for the acceleration of the growth of the virology market. These collaboration aid them to combine expertise in drug development, and innovation in clinical research. This way, pharmaceutical companies are able to use knowledge and advanced technologies of academic and research institutions in finding novel antiviral compounds, understanding viral mechanisms, and optimizing drug formulations.
Other advantages of such partnerships include the opportunity to share scientific data and clinical trials, allowing for better understanding of regulatory procedures and ensuring safe and effective development of new treatments
These partnerships also make it possible for access to expert infrastructure, which includes high-performance laboratories and throughput screening platforms that speed up discovery. Besides that, research centers advance cutting-edge knowledge in areas such as virology, immunology, and genomics and facilitate innovation.
For instance, in February 2023, GSK plc, invested USD 1.5 million in University of Alberta Li Ka Shing Institute of Virology (LKSIoV). The investments are aimed to fund the quest for breakthroughs in antivirals, and vaccines.
Growing Emphasis of Research Institutes towards Development of Diagnostic Tools with Expanded Applications
Research institutes mainly focus on advanced diagnostic tools that identify diseases at an early stage and provide more accurate, quick, and cost-effective results. This extends the possibilities of diagnostics, from general diseases up to very rare cases of genetic ones, and significantly extends the circle of possible clients.
These advances also ease the burden on healthcare systems by facilitating personalized medicine. As diagnostic tools become more specific, health professionals can individualize treatments, which enhances treatment efficacy and minimizes adverse effects. Research into diagnostic tools that have wider applications, such as point-of-care settings or in remote areas, further improves accessibility and leads to better global health outcomes.
The effect of all these changes is a more dynamic, accessible, and diversified market, which attracts investments and creates continuous improvements in diagnostic technologies. For instance, in 2022, Columbia University received approval for the use VirCapSeq in New York State in the United States. This VirCapSeq, can be used for the diagnosis of systemic and respiratory tract infections.
Therefore, growing advancements and the efforts put down by research institutes eventually mark a shift toward broad, versatile diagnostic tools that aid in transforming healthcare delivery which fuels the overall growth of the diagnostic segment in virology market.
The Development of mRNA vaccines for Several Infectious Diseases Presents Significant Growth Opportunities for Manufacturers
mRNA technology has proved extremely effective in the rapid generation of vaccines. This technology allows manufacturers to rapidly adapt and respond to emerging infectious threats, making it an attractive platform for addressing several diseases such as influenza, Zika, and HIV, to viral infections like HPV.
Another important advantage is the scalability of mRNA production. Unlike traditional vaccines, which often require growing the virus in labs or cultivating in eggs, mRNA vaccines can be synthesized in large quantities much more quickly and cost-effectively. This enables manufacturers to meet global demands efficiently, especially in low-resource settings.
In addition, mRNA technology allows the development of vaccines against a number of variants or strains of a virus, which also dispels questions of mutation and resistance. With the increased demand for rapid, and adaptable vaccines, manufacturers with mRNA capabilities have considerable competitive advantages in the virology market. These added advantages allows companies with mRNA vaccine technologies to pose significant growth in both established and emerging market.
High Development and Production Costs Associated with Virology Research for the Development of Vaccines and Other related products hinder Market Growth
Research and development of virology based vaccines and therapies require huge investments and advanced technologies, along with large number of clinical trials, and infrastructure. Such a process for developing the vaccines, using methods like mRNA-based or viral vector vaccines, requires huge scientific research that would take several years and lot of investment. Some costs may eventually dissuade the small biotech firms from stepping into the markets and slowing the innovation in these sectors.
The high costs associated with specialized facilities and expertise in the manufacturing process hinders its further market reach. This makes rapid scaling of production challenging, especially when there is an emerging viral threat.
This cost burden normally falls on the consumer or governments, leading to a lack of access, especially within low- and middle-income countries. In this way, even when efficient products are developed, ultimately their affordability and accessibility hamper the global adoption processes. These financial hindrances ultimately serve to limit the overall market reach by delaying widescale distributions and stalling the overall progress of the growth of the virology market.
The global virology industry recorded a CAGR of 2.7% during the historical period between 2020 and 2024. The growth of virology industry was positive as it reached a value of USD 2,249.5 million in 2024 from USD 2,024.5 million in 2020.
The applications of virology in the areas of vaccine development, such as antiviral therapies, and diagnostic technologies have emerged as a technological forefront. The above mentioned applications highly contribute to the public health by preventing and curing viral infections.
A number of factors such as vaccine development for smallpox and polio, increase in integration of studies in virology for drug development, and growing adoption of anti-viral drugs to meet the rising prevalence of HIV/AIDS, anticipates the growth of the virology research.
Moreover, initiatives made by research institutes and pharmaceutical companies in the current gene-editing technologies like CRISPR and next-generation sequencing further propels the market growth. With time, next-generation sequencing has become better in identifying the viral mutation and outbreaks.
Growth in the future of the virology market is driven by innovations in vaccine platforms, gene therapies, antiviral drugs, and real-time diagnostics. Increasing focus of the government of several countries on preparedness for pandemic conditions, increasing advancements in mRNA technology along with growing focus of manufacturer on the development of immune-based therapies contribute to the growth of the virology market.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 61.6% in global market. These market leaders are characterized by high production capacity and a wide product portfolio. These market leaders are distinguished by their extensive expertise in manufacturing and reconditioning across multiple packaging formats and a broad geographical reach, underpinned by a robust consumer base. Prominent companies within tier 1 include Gilead Sciences, Inc., AbbVie and GSK plc
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 24.4% market share. These are characterized by a strong presence overseas and strong market knowledge. These market players have good manufacturing technology and ensure regulatory compliance but may not have access to global reach. Prominent companies in tier 2 include Amarna Therapeutics, Theolytics and Nektar Therapeutics
Finally, Tier 3 companies, act as a suppliers to the established market players. They are essential for the market as they specialize in specific products and cater to niche markets, adding diversity to the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the virology market remains dynamic and competitive.
The section below covers the industry analysis for the virology market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with a value share of 84.7% through 2035. In Asia Pacific, South Korea is projected to witness a CAGR of 5.4% by 2035
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| UK | 4.4% |
| China | 4.2% |
| Japan | 4.6% |
| South Korea | 5.2% |
| Germany | 5.1% |
| India | 3.8% |
| GCC Countries | 2.4% |
United States virology market is poised to exhibit a CAGR of 6.6% between 2025 and 2035. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.
Key factors driving the market of virology in the US include increasing investment from private organizations and pharmaceutical companies in the field. These investments lead to advanced antiviral therapies, vaccines, and diagnosis technologies to tackle emerging and established viral threats. Private organizations, especially the biotech companies, are highly innovative-which constantly focuses on new frontiers of drug discovery, and development of new vaccine platforms.
In addition, pharmaceutical companies in United States are also emphasizing on expanding their portfolios related to antiviral drugs and vaccines due to increasing demand. This, in turn, is improving technological progress, enhancing healthcare solutions, and ensuring a continuous pipeline of antiviral products, thereby helping increase investment in virology research which contribute to the overall growth of the virology market in the United States
China is anticipated to grow at a CAGR of 4.2% and is anticipated to grow at a substantial CAGR throughout the forecast period.
The growth of the virology market in China is greatly contributed to by emerging and re-emerging viral infections, which raise the demand for vaccines, antiviral treatments, and diagnostic solutions. China is suffering from new viral menaces, such as the recent COVID-19 pandemic, but also from diseases that have been a concern for some time, like influenza, hepatitis, and avian influenza.
The need for rapid detection, effective vaccines, and antiviral drugs to manage these outbreaks propels the market for further growth. Additionally, the heavy population and urbanization of China increase the chances of transmission of viruses, boosting demand for healthcare products related to virology. Increased research, government funding, and international collaboration with health organizations, accelerate innovation in virology, making it one of the major drivers of growth within the country's healthcare market.
Germany is expected to have a strong foothold in the virology market. In 2024 the country is projected to account for substantial share of the virology market. Investment plans made by government by Germany for research and development of vaccines and drugs that are more into prevention of viral diseases majorly anticipate the growth of the market.
For instance, in July 2023, The German Federal Ministry of Education and Research (BMBF) approved funding for five non-profit organizations through KfW. The aim of this funding is to focus on R&D of affordable and accessible vaccines for neglected population. Also, vaccination programs, and the preparedness of the government to handle emerging viral threats through various government-supported public health initiatives, are other factors that increase the demand in the market.
Investments in virology research by the German government, and promoting academic-private collaborations, accelerates solutions to ensure continuous growth in the virology market for the improvement of public health. Therefore, the government support and funding, especially by the government of Germany, is one of the key factors that is subjected to boost the growth of the virology market, as it enhances research, development, and innovation in the field.
The section contains information about the leading segments in the industry. By product type, diagnostic segment hold highest share of the market.
| Product Type | Diagnostic Test |
|---|---|
| Value Share (2025) | 46.4% |
Diagnostic testing is the leading segment in the virology market because of the high importance that it plays in early detection, monitoring, and managing viral infections. Accurate diagnosis and speed form very vital constituents of treatment in outbreaks and pandemics. Growing upsurge of viral diseases such as COVID-19, HIV, and influenza, PCR tests, increase in number of centers conducting antigen tests, growing adoption of next-generation sequencing techniques anticipates the growth of the market.
Early diagnosis allows for timely intervention, improving patient outcomes and helping to contain the spread of infections. Besides, new developments in molecular diagnostics, point-of-care testing, and automation raise accuracy and speed, thereby driving the market further. While viral infections continue to pose a threat to public health, the segment of diagnostic tests plays an indispensable role in virology, both for healthcare providers and public health initiatives.
| End User | Hospitals |
|---|---|
| Value Share (2025) | 58.4% |
The hospitals segment is forecast to account for a share of 58.4% and is poised to expand at a substantial CAGR during the forecast period.
Hospitals are major healthcare facilities that are generally visited by patients in severe or complicated viral infections. They are well facilitated with advanced diagnostic tools and skilled healthcare professionals who can handle critical cases. Besides this, hospitals also act as a major hub for the management of viral diseases, which includes inpatient admission, surgical procedures, and anti-viral therapies.
Though clinics, laboratories, and diagnostic centers are indispensible to the diagnosis and treatment processes, it is the hospitals that dominate by virtue of sheer volume of patients treated and services provided in advanced diagnostics and comprehensive treatment for viral infections.
Substantial investments and focus is seen in the virology industry towards launch of new series of products to the market. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence. In addition, many of the key players are also emphasizing on making strategic investments for accelerating development of their pipeline products.
Recent Industry Developments in Virology Drugs Market
In terms of product type, the industry is divided into diagnostic tests, viral infection controlling methods, antiviral chemotherapy and interferons
In terms of application, the industry is segregated into skin and soft tissue infections, respiratory tract infections, GI tract infections, urinary tract infections, eye infections, CNS infections, sexually transmitted diseases and perinatal infections
The industry is classified by end user as hospitals, clinics, laboratories, diagnostic centres, blood banks and pharmacies
Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa (MEA) have been covered in the report.
The global virology industry is projected to witness CAGR of 5.0% between 2025 and 2035.
The global virology industry stood at USD 2,249.5 million in 2024.
The global virology industry is anticipated to reach USD 3,808.9 million by 2035 end.
South Korea is set to record the highest CAGR of 5.2% in the assessment period.
The key players operating in the global virology industry include Tevogen Bio, R-Biopharm AG, VerImmune Inc, AbbVie, Virogin Biotech Limited, Kineta, Gilead Sciences, Inc., Amarna Therapeutics, Dewpoint Therapeutics, ARS Pharmaceuticals, Abivax, Theolytics, Nektar Therapeutics and GSK plc
Explore Similar Insights
Virology Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
